To include your compound in the COVID-19 Resource Center, submit it here.

AcelRx's Dsuvia gets CRL

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) said FDA issued a complete response letter for its NDA for Dsuvia sufentanil sublingual tablet to

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE